DSM Capital Partners

DSM Capital Partners

DSM Capital Partners was founded in 1992 by Daniel Strickberger and Stephen Memishian, two analysts who previously worked together at Oppenheimer. The firm launched with a focused strategy: concentrate capital into a limited number of publicly traded growth companies and hold through cycles. That discipline has kept the portfolio compact — typically 20 to 25 positions — and the turnover low for over three decades. Strickberger and Memishian remain co-chief investment officers and the binding force behind the investment committee. The strategy centers on bottom-up fundamentals with a heavy tilt toward technology and consumer. DSM's team looks for durable revenue growth, strong management, and scalable business models. The portfolio spans mega-cap compounders like Microsoft and Alphabet alongside mid-cap disruptors in enterprise software, digital health, and fintech. Confirmed positions across regulatory filings have included Workday, Salesforce, Mastercard, Intuitive Surgical, and Dexcom. The firm does not operate private funds, SPVs, or co-investment vehicles — it is a pure-play public equities manager. Geographic exposure leans heavily on US-domiciled companies, with a portion of the book in Western Europe and select emerging-market ADRs. DSM manages concentrated separate accounts for institutions and high-net-worth individuals, alongside a mutual fund and a UCITS vehicle for non-US investors. The firm operates from five US offices: Mountain View, Burlingame, San Francisco, Palm Beach Gardens, and Boston. Headcount remains lean relative to assets, consistent with a research-centric culture that emphasizes analyst-driven sourcing and direct management engagement. In recent years the firm has deepened its footprint in European distribution through the UCITS structure, while the core institutional book has grown via consultant gatekeepers and endowment relationships. The structural differentiator is operational: Strickberger and Memishian have run the same strategy without a generational handoff for more than 30 years. Succession risk is the open question. The firm's mandate is narrowly defined — no private markets, no credit, no real assets — which limits product diversification but eliminates style drift. For allocators seeking a pure growth-equity sleeve with founder-cycle consistency, DSM's architecture remains rare among managers of comparable scale.